Bio-Techne Corporation (TECH) saw a decline after weak Q4 Results, with shares being purchased by several reputable parties including Victory Capital Management Inc. and Truist Financial Corp. A new
distribution agreement with Thermo Fisher Scientific has been announced, and the company's estimated intrinsic value is potentially higher than its shares. The corporation has also released its
third quarter fiscal 2024 results and declared a dividend. In a pertinent move, Bio-Techne has filed a
patent infringement lawsuit against Molecular Instruments. The company announced multiple partnerships, including ones with Novomol-Dx for point-of-care ocular biomarker assay, and Nikon Instruments Inc.
Dr. Judith Klimovsky has also been appointed to the board of directors. Lastly, the corporation has been certified by European IVDR for a diagnostic test to monitor chronic diseases.
Bio-Techne Corp TECH News Analytics from Thu, 04 Aug 2022 07:00:00 GMT to Thu, 16 May 2024 18:06:53 GMT -
Rating 6
- Innovation 8
- Information 6
- Rumor 2
